Cord Blood News Volume 9.01 | Jan 12 2017

TOP STORY

Dissociation of Survival, Proliferation, and State Control in Human Hematopoietic Stem Cells

The role of growth factors (GFs) in controlling the biology of human hematopoietic stem cells (HSCs) remains limited by a lack of information concerning the individual and combined effects of GFs directly on the survival, mitogenesis, and regenerative activity of highly purified human HSCs. Researchers showed that the initial input HSC activity of such a purified starting population of human cord blood cells can be fully maintained over a 21-day period in serum-free medium containing five GFs alone. [Stem Cell Reports] Full Article | Graphical Abstract

(Ranked by impact factor of the journal)

EID3 Directly Associates with DNMT3A during Transdifferentiation of Human Umbilical Cord Mesenchymal Stem Cells to NPC-Like Cells

Researchers transdifferentiated human umbilical cord mesenchymal stem cells (UMSCs) into neural stem-like cells (uNSCL), these cells grow in neurosphere-like structures and express high levels of NSCs markers. Epigenetics-related gene screening was used to assess the relationship between E1A-like inhibitor of differentiation 3, a p300 inhibitor, and DNA methyltransferase 3 A during the transdifferentiation of UMSCs into uNSCL in vitro. [Sci Rep] Full Article

Therapeutic Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Acute Lung Injury Mice

Researchers found that intratracheal administration of human umbilical cord-mesenchymal stem cells significantly improved survival and attenuated the lung inflammation in lipopolysaccharide-induced acute lung injury mice. [Sci Rep] Full Article

The Protein Content of Extracellular Vesicles Derived from Expanded Human Umbilical Cord Blood-Derived CD133⁺ and Human Bone Marrow-Derived Mesenchymal Stem Cells Partially Explains Why Both Sources Are Advantageous for Regenerative Medicine

Investigators profiled the protein content of extracellular vesicles (EVs) derived from expanded human CD133⁺ cells and bone marrow-derived human mesenchymal stem cells with the intention of better understanding the functions performed by these vesicles/cells and delineating the most appropriate use of each EV in future therapeutic procedures. [Stem Cell Rev Rep] Full Article

Targeted Genome Engineering to Control VEGF Expression in Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells: Potential Implications for the Treatment of Myocardial Infarction

The authors generated an inducible vascular endothelial growth factor (VEGF)-secreting stem cell (VEGF/human umbilical cord blood-derived mesenchymal stem cells) that controls the expression of VEGF and tested the therapeutic efficacy in rat myocardial infarction (MI) model to apply functional stem cells to MI. [Stem Cells Transl Med] Abstract

Enhanced Chondrogenic Differentiation of Human Umbilical Cord Wharton’s Jelly Derived Mesenchymal Stem Cells by GSK-3 Inhibitors

Scientists investigated the influence of lithium chloride and SB216763 synergistically with TGF-β3 on chondrogenic differentiation in human mesenchymal stem cells derived from Wharton’s jelly tissue. [PLoS One] Full Article

Intracavernous Injection of Human Umbilical Cord Blood Mononuclear Cells Improves Erectile Dysfunction in Streptozotocin-Induced Diabetic Rats

Erectile dysfunction (ED) worsens in men with diabetes. Human umbilical cord blood (HUCB), because of its widespread availability and low immunogenicity, is a valuable source for stem cell-based therapies. To determine the effect of intracavernous injection of HUCB mononuclear cells on ED in rats with diabetes induced by streptozotocin. [J Sex Med] Abstract

Physical Properties and Biological Interactions of Liposomes Developed as a Drug Carrier in the Field of Regenerative Medicine

Investigators examined the effect of charged conventional liposomes on growth of mesenchymal and blood stem cells isolated from umbilical cord. [J Liposome Res] Abstract

Preleukemia: One Name, Many Meanings

Investigators noted that acute myeloid leukemia (AML) patients who achieved complete morphological remission after chemotherapy often have clonal hematopoiesis predominantly marked by either DNMT3A, TET2 or IDH1/2 mutations, which were also present at diagnosis of AML. This preleukemic clone represents involvement of early hematopoietic stem cells, which is resistant to standard therapy. The same clonal hematopoietic mutations have been identified in older ‘normal’ individuals who have a modest increased risk of developing frank AML. These individuals have occasionally been said, probably inappropriately, to have a preleukemia clone [Leukemia] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

HemaCare and OneBlood Announce Innovative Partnership

HemaCare Corporation has announced a strategic partnership with and investment by a wholly-owned subsidiary of OneBlood, Inc. [Hemacare Corporation] Press Release

Johnson & Johnson Innovation, New York State and New York Genome Center Collaborate to Launch JLABS in New York City

Johnson & Johnson Innovation LLC, New York State and the New York Genome Center announced a collaboration to launch a new JLABS in New York City. Called JLABS @ NYC, the 30,000-square foot facility will be located at the New York Genome Center in SoHo and will open in 2018. The project is receiving $17 million in New York State funding. [Johnson & Johnson Innovation LLC] Press Release

White House Announces Review Process for Risky Virus Studies

Federal officials released a plan to help U.S. agencies decide whether to fund controversial studies that make viruses more dangerous. The guidance may finally bring an end to a moratorium that has kept a handful of experiments funded by the Department of Health and Human Services on hold for more than two years. [ScienceInsider] Editorial

US Energy Agency Strengthens Protections for Scientists

The US Department of Energy has released new guidelines to protect researchers from political interference — a move that many say is long overdue. [Nature News] Editorial

Cleveland Clinic Will Discipline Doctor Who Wrote Antivaccination Column

The Cleveland Clinic released an apology from a staff physician who published an antivaccination column on the news website Cleveland.com. The doctor, Daniel Neides, will be “appropriately disciplined,” the Ohio hospital added in its own statement, which noted that the family physician’s views do not reflect his institution’s. [ScienceInsider] Editorial

NEW Epigenetic Regulation of Stem Cell Differentiation
March 1, 2017
Amsterdam, The Netherlands

NEW The Future of Regenerative Medicine Congress: Extending and Improving Life with Perinatal, Adipose and Bone Marrow Cellular Therapy
May 19-21, 2017
Teaneck, United States

Visit our events page to see a complete list of events in the community.

NEW Scientist Position – Immunology (New York Blood Center)

Full Member Faculty – Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center)

Instructor – Molecular and Cellular Pathology (The University of Alabama)

Research Fellow – Neurobiology (Biomedical Institute for Global Healthcare Research & Technology)

Postdoctoral Research Fellow – Gastrointestinal Research (Boston Children’s Hospital; Harvard Medical School)

Postdoctoral Position – Mesenchymal Stem Cells (University of Southern California)

Principle Scientist – Translational Development (Celgene Corporation)

Postdoctoral Researcher – Epigenetics/Systems Biology (National Heart, Lung and Blood Institute, National Institutes of Health)

Assistant Associate or Full Member Faculty Position – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Assistant Member Faculty – Platinum/Immunotherapy (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here.